PARTNER NEWS:Thu, Mar 14, 10:07 AM, Zacks
Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More
Amylyx Pharmaceuticals (AMLX) and Acadia Pharmaceuticals (ACAD) plunged on failure of studies.
Wed, Mar 13, 10:09 AM, Zacks
Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study
Data from an early-stage study shows that treatment with Regulus (RGLS) lead drug shows increased biological activity at a higher dose in patients with autosomal dominant polycystic kidney disease.